MedTrace Logo

Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

NCT05910710 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2023-06-20

No results posted yet for this study

Summary

It analyzes the Tumor microenvironment(TME) changes in non pathologic complete response(pCR) subjects among subjects who were administered neoadjuvant pembrolizumab and those who were not administered neoadjuvant pembrolizumab for triple negative breast cancer.

(Neoadjuvant Weekly paclitaxel, Carboplatin +- Pembrolizumab followed by Doxorubicin, Cyclophosphamide +- Pembrolizumab regimen)

Conditions

Interventions

GENETIC

Visium, Whole Genome Sequencing(WGS)/Whole Transcriptome Sequencing(WTS)

Visium : Spatial transcriptomics WGS/WTS : detection of somatic mutation

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-02
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05910710 on ClinicalTrials.gov